Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718464 | 1.00 | PGR (0.60) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL29860346 | 0.87 | PGR (0.72) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL2144125 | 0.87 | PGR (0.72) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL9395642 | 0.84 | GRIA1 (0.57) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL31439101 | 0.84 | GRIA1 (0.57) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL31439102 | 0.84 | GRIA1 (0.57) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL4980076 | 0.83 | SIRT2 (0.63) | PGRSIRT2GRIA1GRIA2GRIA3 | |
| SCHEMBL20567992 | 0.81 | MAPT (0.57) | PGRGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL10138692 | 0.81 | LMNA (0.47) | PGRSIRT2LMNAMAPTDAO | |
| SCHEMBL25403172 | 0.80 | PGR (0.63) | PGRSIRT2GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| WO-2025096771-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119894878-A | Aromatic amide derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4536350-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | Nodthera Limited (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-119431394-A | Pyridazinone derivatives and medical application thereof | 杭州百新生物医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| CN-118561812-A | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-111163839-B | Benzimidazolone-derived BCL6 inhibitors | 癌症研究科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117980290-A | Cyanopyridine and cyanopyrimidine BCL6 degrading agents | 达纳－法伯癌症研究所公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117917405-A | KIF18A protein inhibitors | 杭州邦顺制药有限公司 | 2024-04-23 | — | — | CN | disclosed |
| WO-2024078569-A1 | AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2023240134-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NodThera Limited (GB) | 2023-12-14 | — | — | WO | disclosed |
| CN-116997550-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same and application thereof | 杭州普洛药物研究院有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-114671856-B | Polysubstituted uracil derivative and use thereof | 广东东阳光药业股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115867277-A | Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof | 韩国科学技术研究院 | 2023-03-28 | — | — | CN | disclosed |
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114853659-A | N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof | 普洛药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114671856-A | Polysubstituted uracil derivatives and their use | 广东东阳光药业有限公司 | 2022-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | PGR 593/4885SIRT2 1520/4885GRIA1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.